PT Sampharindo Retroviral Indonesia focuses it business in antiretroviral drugs and manufacturing facilities are dedicated for it. This is in line with our commitment to the Indonesia GMP regulations, commitment to quality, and commitment to the environment. The main production area, packaging and warehouse surrounded by a secondary / buffer area to maintain product safety from environmental contamination and vice versa. With adequate warehouse capacity and separate storage location for raw materials, packaging materials and finished products, we have a validated inventory system to ensure the quality of stored materials and products. Introduction Human Immunodeficiency Virus (HIV) transmission is increasing every year. In 2015, HIV in Indonesia has an incidence of 600,000 peoples and increasing. With the number of patients diagnosed as many as 200,000 patients. While the number of patients who have received HIV treatment are only 51,300 patients. The government of Indonesia launched the HIVAIDS therapy program since 1987. Indonesia import HIVAIDS drugs from some countries. Due to developing new molecules of API for antiretroviral therapy and also the previous products cause of resistance for some patients, facing those challenge PT Sampharindo Retroviral Indonesia established in 2017. In order supporting program in HIVAIDS therapy. We produce second & third generation of antiretroviral PT Sampharindo Retroviral Indonesia is certain to be able to respond to the government needs for antiretroviral products, ensuring that patients get quality drugs produced domestically, there by reducing the number of imported drugs.
